Medications for urinary retention
Pro Research Analysisby 
Searched over 200M research papers
Medications Associated with Urinary Retention
Urinary retention can be caused or worsened by a wide range of medications. Large-scale pharmacovigilance studies and adverse event reporting systems have consistently identified several drug classes and specific agents linked to urinary retention. These include anticholinergics, antidepressants (such as SNRIs and SSRIs), opioids, antineoplastic agents, antidiabetic drugs, calcium channel blockers, and certain newer agents for overactive bladder like β3-adrenoceptor agonists 1245+1 MORE. Drugs such as fesoterodine, mirabegron, solifenacin, tiotropium, quetiapine, amlodipine, duloxetine, desvenlafaxine, and ezogabine have shown particularly strong associations with urinary retention 1235+1 MORE. Newer signals have also been detected for drugs like abiraterone, fluoxetine, empagliflozin, dapagliflozin, gabapentin, lithium, celecoxib, and piroxicam, highlighting the need for ongoing monitoring 124.
Medications for Treating Urinary Retention
Alpha-Blockers for Benign Prostatic Obstruction
For urinary retention caused by benign prostatic obstruction (BPO), alpha-blockers such as alfuzosin and tamsulosin are the most studied and effective pharmacological options. These medications significantly increase the chances of successful voiding without a catheter compared to placebo, with relatively few adverse events . They are recommended as first-line pharmacological therapy in this context.
Other Pharmacological Treatments
Other drug classes have been explored for post-operative or acute urinary retention, including cholinergic agents, sedatives, and prostaglandins. Evidence suggests that intravesical prostaglandin and combinations of cholinergic agents with sedatives may improve spontaneous voiding, but the overall quality of evidence is weak and further research is needed . In remote or resource-limited settings, a combination of tamsulosin (an alpha-blocker) and lorazepam (a benzodiazepine) has been used successfully as a temporary measure when catheterization is not immediately possible .
Special Considerations and Monitoring
Risk Factors and Monitoring
The risk of drug-induced urinary retention is higher in older adults, males, and those with underlying conditions such as benign prostatic hyperplasia or diabetes 1410. The onset of urinary retention after starting a new medication is often rapid, with many cases occurring within the first month 110. Patients taking multiple medications that can cause retention, especially in palliative care or at the end of life, should be closely monitored, with particular attention to antidopaminergic drugs, which have a stronger association with retention than other classes .
Overactive Bladder Medications
Selective β3-adrenoceptor agonists (such as mirabegron and vibegron), while effective for overactive bladder, can also cause urinary retention, especially when combined with other medications that increase urethral resistance or in patients with pre-existing urinary tract obstruction . Careful review of concomitant medications and underlying conditions is essential when prescribing these agents.
Conclusion
A wide variety of medications can cause or worsen urinary retention, with anticholinergics, antidepressants, opioids, and certain newer agents being most frequently implicated. For treatment, alpha-blockers like alfuzosin and tamsulosin are the best-supported options, particularly for retention due to benign prostatic obstruction. Other pharmacological treatments may be considered in specific situations, but evidence is limited. Ongoing monitoring and individualized risk assessment are crucial, especially when starting new medications in at-risk populations.
Sources and full results
Most relevant research papers on this topic